Abstract
This study explored the relationships of serum insulin-like growth factors, IGF-I and IGF-II, and their binding proteins (IGFBP)-2 and IGFBP-3, with key clinicopathological parameters in 92 patients with colorectal cancer (cases). Comparisons were made with 57 individuals who had a normal colonoscopy (controls). Serial changes were examined in 27 cases. As IGF-related peptides are age- and sex-dependent, absolute concentrations were converted to standard deviation scores (SDS). Mean IGF-II SDS were elevated in Dukes A (n= 12P< 0.001) and Dukes B (n= 25P< 0.001) cases compared with controls, but not in advanced disease. Compared with controls, mean IGFBP-2 SDS were significantly elevated in patients with Dukes B (P< 0.001), Dukes C (n= 13P< 0.001) and advanced disease (n= 42P< 0.0001), with a significant trend from early to advanced disease (one-way ANOVAP< 0.001). Furthermore, IGFBP-2 SDS were positively related to tumour size (P= 0.01) and fell significantly in patients following curative resection (P= 0.04), suggesting that circulating levels reflect tumour load. We tested the potential tumour marker characteristics of IGFBP-2 SDS against three endpoints: metastasis alone; local pelvic recurrence alone; and metastasis and recurrence combined. The sensitivities for IGFBP-2 alone (≥ + 2SD) were modest at 55%, 46%, and 52%, but in combination with CEA, increased substantially to 90%, 77% and 86%, respectively. We conclude that the serum IGF-II and IGFBP-2 profiles may provide insights into underlying biological mechanisms, and that serum IGFBP-2 may have an adjunct role in cancer surveillance in patients with colorectal cancer. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adenis A, Peyrat JP, Hecquet B, Delobelle A, Depadt G, Quandalle P, Bonneterre J and Demaille A (1995) Type I insulin-like growth factor receptors in human colorectal cancer. Eur J Cancer 31a: 50–55
Arai T, Busby W Jr and Clemmons DR (1996) Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 137: 4571–4575
Baciuchka M, Remacle Bonnet M, Garrouste F, Favre R, Sastre B and Pommier G (1998) Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: possible association with the metastatic potential of the tumor. Int J Cancer 79: 460–467
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH and Polak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563–566
Clemmons DR (1997) Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8: 45–62
Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR and Rosenfeld RG (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76: 1031–1035
el Atiq F, Garrouste F, Remacle Bonnet M, Sastre B and Pommier G (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57: 491–497
Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E and Raz I (1999) Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 44: 704–708
Gockerman A and Clemmons DR (1995) Porcine aortic smooth muscle cells secrete a serine protease for insulin-like growth factor binding protein-2. Circ Res 76: 514–521
Hammerlid E, Wirblad B, Sandin C, Mercke C, Edstrom S, Kaasa S, Sullivan M and Westin T (1998) Malnutrition and food intake in relation to quality of life in head and neck cancer patients. Head Neck 20: 540–548
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396
Ho PJ and Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 46: 333–342
Hoeflich A, Lahm H, Blum W, Kolb H and Wolf E (1998) Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett 434: 329–334
Hoeflich A, Fettscher O, Lahm H, Kolb H, Wolf E, Engelhardt D and Weber MM (2000) Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorogenic potential in Y-1 adrenocortical tumor cells. Cancer Res 60: 834–838
Jass JR and Sobin LH (1989). Histological typing of intestinal tumors, 2nd edn, World Health Organisation: Geneva
Jones JI and Clemmons DR (1995) lnsulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3–B4
Juul A, Main K, Blum WF, Lindholm J, Ranke MB and Skakkebaek NE (1994) The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 41: 85–93
Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J and Karasik A (1996) Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 73: 1069–1073
Kawamoto K, Onodera H, Kondo S, Kan S, Ikeuchi D, Maetani S and Imamura M (1998) Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival. Oncology 55: 242–248
Lahm H, Amstad P, Wyniger J, Yilmaz A, Fischer JR, Schreyer M and Givel JC (1994) Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 58: 452–459
Lambert S, Carlisi A, Collette J, Franchimont P and Gol Winkler R (1992) Insulin-like growth factor II in two human colon-carcinoma cell lines: gene structure and expression, and protein secretion. Int J Cancer 52: 404–408
Le Roith D (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336: 633–640
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH and Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620–625
Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65: 311–320
Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO and Mantzoros C (1999) IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83: 15–17
Mishra L, Bass B, Ooi BS, Sidawy A and Korman L (1997) Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Regulation 7: 1–10
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA and Tangen C (1993) An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270: 943–947
Mohnike KL, Kluba U, Mittler U, Aumann V, Vorwerk P and Blum WF (1996) Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 155: 81–86
Muller HL, Oh Y, Lehrnbecher T, Blum WF and Rosenfeld RG (1994) Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 79: 428–434
Rajaram S, Baylink DJ and Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18: 801–831
Reeve JG, Payne JA and Bleehen NM (1990) Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours. Br J Cancer 61: 727–731
Renehan AG and O'Dwyer ST (2000) Surveillance after colorectal cancer resection. Lancet 355: 1095–1096
Renehan AG, Painter JE, O'Halloran D, Atkin WS, Potten CS, O'Dwyer ST and Shalet SM 2000a) Circulating insulin-like growth factor (IGF)-II and colorectal adenomas. J Clin Endocrinol Metab 85: 3402–3408
Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM and O'Dwyer ST 2000b) ‘high-risk’ colorectal adenomas and serum insulin-like growth factors. Br J Surg,
Singh P, Dai B, Yallampalli U, Lu X and Schroy PC (1996) Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. Endocrinology 137: 1764–1774
Taylor AM, Dunger DB, Preece MA, Holly JM, Smith CP, Wass JA, Patel S and Tate VE (1990) The growth hormone independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetics. Clin Endocrinol Oxf 32: 229–239
Thissen JP, Ketelslegers JM and Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocr Rev 15: 80–101
Toogood AA, Jones J, PA O'Neill,, Thorner MO and Shalet SM (1998) The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol Oxf 48: 569–576
Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, Bell GI and Shows TB (1986) Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 46: 6169–6173
Turnbull R, Kyle K and Watson F (1967) Cancer of the colon: the influence of the no-touch technique on survival rates. Ann Surg 166: 420–427
Wang JY, Tang R and Chiang JM (1994) Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 37: 272–277
Wex H, Vorwerk P, Mohnike K, Bretschneider D, Kluba U, Aumann V, Blum WF and Mittler U (1998) Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer 78: 515–520
Wolf RF and Cohen AM (1997) The miniscule benefit of serial carcinoembryonic antigen monitoring after effective curative treatment for primary colorectal cancer. J Am Coll Surg 185: 60–64
Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J and Juul A (1999) Insulin-like growth factors (IGF-I, Free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Analysis 13: 166–172
Zumkeller W, Schwander J, Mitchell CD, Morrell DJ, Schofield PN and Preece MA (1993) Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. Eur J Cancer 29a: 1973–1977
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Renehan, A., Jones, J., Potten, C. et al. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 83, 1344–1350 (2000). https://doi.org/10.1054/bjoc.2000.1462
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1462
Keywords
This article is cited by
-
Effects of long-term sex steroid hormones (estradiol and testosterone)–supplemented feeds on the growth performance of Chinese tongue sole (Cynoglossus semilaevis)
Fish Physiology and Biochemistry (2022)
-
IGFBP2: integrative hub of developmental and oncogenic signaling network
Oncogene (2020)
-
IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma
Oncogene (2019)
-
IGF-binding protein 2 is a candidate target of therapeutic potential in cancer
Tumor Biology (2016)
-
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
British Journal of Cancer (2012)